BridgeMD
New treatment option for Pain, Chronic
Official title Relieving Chronic Pain in Older Adults With Transcranial Direct Current Stimulation
ClinicalTrials.gov ID: NCT05617027
What this study is testing
- What it's testing
- The primary objective of this study is to determine, in a healthcare setting, the effectiveness of actual tDCS in reducing pain compared with placebo tDCS. This is a multicenter randomized controlled trial with parallel groups (real tDCS vs.
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 65 and older
You may be able to join if
- Be aged ≥ 65 years
- Have chronic (≥ 6 months) musculoskeletal pain of moderate to severe intensity (≥4 out of 10 on a numerical scale of 0 to 10)
You likely can't join if
- Those with contraindications to tDCS
- Those with contraindications to TMS
- Those with contraindications to IRM
- Individuals for whom the procedure could cause impairment of well-being, or has another medical condition that could put them at risk in the judgment...
- Patients taking medications that act on the GABAergic and glutamatergic systems (modulating tDCS effects) will be excluded
- Individuals taking other types of medications or receiving rehabilitation are not excluded but will be asked, in the absence of clinical...
See the full eligibility criteria
- Be aged ≥ 65 years
- Have chronic (≥ 6 months) musculoskeletal pain of moderate to severe intensity (≥4 out of 10 on a numerical scale of 0 to 10)
- Those with contraindications to tDCS
- Those with contraindications to TMS
- Those with contraindications to IRM
- Individuals for whom the procedure could cause impairment of well-being, or has another medical condition that could put them at risk in the judgment of a health care professional.
- Patients taking medications that act on the GABAergic and glutamatergic systems (modulating tDCS effects) will be excluded
- Individuals taking other types of medications or receiving rehabilitation are not excluded but will be asked, in the absence of clinical contraindication, to avoid any modification (e.g., new treatment, discontinuation...
- People with epilepsy and seizures will not be excluded from the study. The research team will simply be asked to pay closer attention to these participants during the administration of MST.
The study team makes the final eligibility decision.
Where it's taking place
- Montreal, Quebec, Canada
- Québec, Quebec, Canada
- Sherbrooke, Quebec, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Montreal, Quebec, Canada; Québec, Quebec, Canada; Sherbrooke, Quebec, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.